194 results about "Thyroid cancer" patented technology

The invention relates to the field of medical informatization. The invention discloses a thyroid cancer electronic medical record system based on multi-modal data fusion. The thyroid cancer electronic medical record system comprises a multi-modal data acquisition module which acquires patient texts, ultrasonic images, genes, biochemical indexes and clinical data and performs standardized calibration to generate standard data; the multi-modal feature extraction module extracts semantic, structure, mutation, change and fluctuation features of each standard data through multiple technologies; the single-mode prediction model construction module constructs single-mode prediction models of texts, images and the like based on the features and outputs results; and the multi-modal fusion prediction module fuses the single-modal model based on the deep learning framework to output a multi-modal fusion prediction result. According to the invention, multi-modal data are integrated, and the accuracy and comprehensiveness of thyroid cancer diagnosis are improved. The system ensures consistency through standardized data processing, and assists doctors to accurately judge pathological types, recommend therapeutic schedules and evaluate prognosis by means of a multi-modal feature extraction and fusion mechanism.

The invention provides a thyroid cancer auxiliary diagnosis and metastasis risk prediction method based on deep learning, and relates to the technical field of artificial intelligence auxiliary medical treatment, and the method comprises the steps: extracting ultrasonic image multi-scale features through a self-adaptive neural architecture search network, combining clinical examination data, fusing diagnosis and treatment knowledge through a neural symbol inference device, and carrying out the prediction of the metastasis risk. Generating a knowledge enhancement feature map; constructing a feature propagation field by using a dynamic neural field network, solving a dynamic evolution equation, and generating a spatial-temporal feature field representing the dynamic change of focus features; constructing a tumor diffusion kinetic model by using an implicit neural representation network and a nerve ordinary differential equation network, calculating a transition probability based on an optimal transmission algorithm, solving an optimal control equation, and outputting a metastasis risk prediction result of each organ; the thyroid cancer diagnosis accuracy and metastasis risk prediction reliability can be effectively improved, and doctors can be assisted in accurate diagnosis and treatment.

The invention discloses a thyroid cancer pathological image classification method and system based on multi-modal feature fusion and Bayesian optimization, and relates to the technical field of medical image processing, and the method comprises the steps: collecting a thyroid ultrasound image data set, and carrying out the preprocessing operation; extracting an improved local binary pattern feature, a Haralick texture feature and a VGG16 depth feature, and constructing a mixed feature space; and splicing the features in the mixed feature space into a 4119-dimensional mixed feature vector, and carrying out feature importance screening by utilizing ExtraTres. Improved local binary pattern features, Haralick texture features and VGG16 depth features are fused, a mixed feature space is constructed, feature importance screening and PCA dimension reduction are performed by using ExtraTrees, multi-level features of the image are effectively extracted, the accuracy of benign and malignant thyroid nodule classification is remarkably improved, meanwhile, network hyper-parameters are dynamically adjusted through a Bayesian optimization algorithm, and the classification accuracy of benign and malignant thyroid nodules is improved. And model convergence is accelerated in combination with a cosine annealing strategy, so that the generalization ability of the model is enhanced, and the model can be excellently expressed on different data sets.

The present invention addresses the problem of providing a novel compound that has a thyroid-stimulating hormone receptor antagonistic activity and is useful for the treatment of thyroid-related diseases. The present invention relates to a nitrogen-containing condensed ring compound represented by formula (A-I) or a pharmacologically acceptable salt thereof. The present invention relates to a nitrogen-containing condensed ring compound represented by formula (A-I) or a pharmacologically acceptable salt thereof. The compound or the pharmacologically acceptable salt thereof according to the present invention has an antagonistic activity against thyroid-stimulating hormone receptors and is therefore useful as a therapeutic agent for thyroid-related diseases (e.g., hyperthyroidism, Graves' disease, thyroid eye disease, and thyroid cancer) and others.

The invention discloses a differentiated thyroid cancer lung metastasis risk prediction model construction method and system. 4D Label-free quantitative proteomics analysis and PRM and IHC dual verification are carried out on primary focus paraffin embedded tissue samples of lung metastatic DTC patients and non-lung metastatic DTC patients, and it is found that multiple key differential expression proteins DEPs may become potential biomarkers for predicting the DTC lung metastasis risk. In addition, the sample size is enlarged, three single and combined DTC lung metastasis risk prediction models are respectively constructed based on clinical features and key DEPs expression, then internal verification is performed on the efficiency of the three fitted models, and the optimal model is taken to construct Nomogram. According to the method, help is provided for risk stratification of lung metastasis of DTC patients, and an important basis is provided for formulating clinical individualized treatment schemes and follow-up visit strategies for high-risk patients.

The invention relates to the technical field of virtual reality, in particular to a thyroid cancer postoperative intelligent follow-up management system, which comprises a wound feature construction module for acquiring a thyroid cancer postoperative patient wound image, extracting a wound edge contour coordinate point set, calculating a wound region area and acquiring a wound morphological parameter set; based on the wound morphological parameter set, the healing progress percentage is analyzed, and a wound dynamic evaluation matrix is established. According to the method, intelligent upgrading of postoperative rehabilitation management is achieved by collecting wound characteristics, calculating the healing progress, matching the nursing track, synchronizing the virtual reality environment, optimizing follow-up scheduling and establishing remote interaction. High-precision dynamic healing evaluation is provided for extraction of the edge contour of the wound and calculation of morphological parameters, and errors caused by judgment depending on experience are avoided. Nursing actions are combined with space coordinate conversion and real-time trajectory optimization, it is ensured that rehabilitation training of the patient has a standardized execution mode, and the situation that the recovery progress is affected by random operation is avoided.

The invention provides an engineered membrane coated nano drug delivery system and application thereof, and belongs to the technical field of nano biomedices.The drug delivery system comprises an inner core combined with a drug, the inner core is coated with a cell membrane, based on the nano drug loading technology and the membrane coating technology, DOX and SRF are loaded on mPDA mesoporous nanoparticles, and thyroid cancer synergistic killing nanoparticles mPDS are formed; the bionic drug delivery system is characterized in that mPDS is used as a target drug delivery system, mPDS is coated with a genetically engineered tumor cell membrane, a dual-targeting membrane-coated nano drug delivery system (mPDS-coated CAR-M) is obtained, and the bionic drug delivery system can penetrate through thyroid cancer in a targeted manner, gather in a focus and reduce side effects of chemotherapy; when near-infrared irradiation is carried out on local tumor, DOX and SRF in mPDS are released, the synergistic effect of photothermal therapy-chemotherapy-targeted therapy is achieved, and the thyroid cancer is killed synergistically.

The invention discloses a thyroid cancer analysis method and device based on real-time fluorescent quantitative PCR. The method comprises the following steps: acquiring to-be-analyzed data; determining sample exclusive threshold line data according to the to-be-analyzed data; calculating a corrected Ct value based on double inflection point dynamics according to the exclusive threshold line data of the sample so as to obtain a final corrected Ct value; and generating a detection result according to the final corrected Ct value. Through optimization processing of the curve fitting algorithm, the linear characteristic of the fluorescence amplification curve is remarkably improved, the interference of background noise on the result is reduced, and the calculation stability of the Ct value is improved.

The invention relates to the technical field of medical risk assessment, in particular to a thyroid cancer risk assessment system and device based on multiple modes. The system comprises a data preprocessing module used for unifying formats and scales of radiomics images, transcriptomics data and clinical medicine texts; the multi-modal feature extraction module is used for extracting image data features by adopting 3D ResNet-34 as a bottom feature extractor and combining a deformable convolution technology; performing feature selection on the exosome miRNA data through a machine learning model, and performing importance sorting on features through an SHAP method; performing feature extraction on the clinical medicine text data through a multi-granularity semantic fusion network architecture; the cross-modal dynamic fusion module is used for aligning and fusing features; and the decision and interpretability module is used for generating a diagnosis result and providing interpretability analysis. According to the technical scheme, the accuracy and efficiency of thyroid cancer risk assessment can be improved.

To provide a pharmaceutical composition comprising a novel compound which has a thyroid-stimulating hormone receptor antagonist activity and is useful for the treatment of thyroid-related diseases.SOLUTION: There is provided a pharmaceutical composition comprising a 3,4-dihydroquinolin-2(1H)-one compound represented by a formula (I) or a pharmacologically acceptable salt thereof. A pharmaceutical composition comprising the compound or the pharmacologically acceptable salt thereof has an antagonist activity against thyroid-stimulating hormone receptors and is useful as a therapeutic agent or the like for thyroid-related diseases (for example, hyperthyroidism, Graves' disease, thyroid eye disease and thyroid cancer).SELECTED DRAWING: None

Theranostic targeted ultrasonic blasting nano-bubbles, a preparation method therefor, and use thereof, wherein the nano-bubbles are the targeted drug-gene nano-bubbles miRNA / FTY720 / PFP@PEI-T7 NBs. The nano-bubbles can be used for preparing a thyroid ultrasound diagnostic agent or a drug for treating thyroid cancer.

A nitrogen-containing polycyclic fused ring compound of formula I, a pharmaceutical composition thereof, a preparation method therefor and use thereof are related to the field of medicinal chemistry. The compound can be used as a selective and effective RET inhibitor. It has strong inhibitory effect on the RET gatekeeper residue mutant RET V804M, RET solvent-front residue mutant RET G810R and other clinically relevant RET mutants, as well as RET wt. The compound can also inhibit the growth of TT cell line derived from thyroid cancer and Ba / F3 cells transformed with various RET mutants, and induce the death of TT cells.

The present invention addresses the problem of providing a novel compound that has a thyroid-stimulating hormone receptor antagonistic activity and is useful for the treatment of thyroid-related diseases. The present invention relates to an N-substituted cyclic amide compound represented by the formula or a pharmacologically acceptable salt thereof. The compound or the pharmacologically acceptable salt thereof according to the present invention has a thyroid-stimulating hormone receptor antagonistic activity and is useful as a therapeutic agent for thyroid-related diseases (e.g., hyperthyroidism, Graves' disease, thyroid eye disease, and thyroid cancer) and others.

Therapeutic compositions comprising chitosan-derived compositions are useful agents when administered in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.

The invention relates to the field of disease risk prediction models, and discloses a thyroid cancer metastasis risk prediction model and a construction method and application thereof. The construction method of the model comprises the following steps: S1, collecting and preprocessing a sample; s2, gene expression quantity detection; s3, data set division and standardization processing; s4, constructing a deep learning model; s5, performing model evaluation; and the biomarker group for detecting the gene expression quantity in the S2 is composed of RPS4Y1, PKHD1L1, CRABP1, KRT18P8, AGPAT4, CPQ, SLC26A7 and RBP4. The prediction model can be used as a clinical auxiliary diagnosis tool and is used for guiding operation range selection, postoperative follow-up visit strategy making and early intervention of high-risk patients, and the precise diagnosis and treatment level of thyroid cancer is improved.

The invention relates to the technical field of tumor molecular imaging, nuclear medicine diagnosis and targeted therapy, and discloses a Trop2-targeted polypeptide, a Trop2-targeted molecular probe and application of the Trop2-targeted polypeptide and the Trop2-targeted molecular probe. The polypeptide can be coupled with different imaging elements to construct molecular probes or radiopharmaceuticals for tumor targeted imaging, so that noninvasive visual detection on the Trop2 expression level in tumor tissues is realized. The probe can specifically recognize Trop2 positive solid tumors, and a new technical means is provided for noninvasive diagnosis and dynamic monitoring of various Trop2 high-expression tumors such as pancreatic cancer, lung cancer, breast cancer and thyroid cancer. The probe disclosed by the invention has the advantages of simple preparation process, low cost, high specificity and stability, short imaging period, low radiation dosage, easiness in clinical transformation and the like, and has a wide application prospect in precise diagnosis and individualized treatment of tumors.

The invention relates to the technical field of intelligent rehabilitation monitoring, in particular to a real-time sticking and pricking effect monitoring system for thyroid cancer postoperative neck and shoulder function rehabilitation, which comprises a vector sequence generation module, a convergence section construction module, a direction difference calculation module, a stable section screening module and an effect monitoring module. According to the method, continuous image frames are collected, a grid observation node shadow direction vector sequence is extracted, the shadow flow trend caused by skin surface microscopic deformation is captured, and the relative deviation between the static texture main direction and the dynamic shadow vector angle is used for representing the real-time coupling degree of the sticking structure and the skin texture. Stable continuous time slices are screened through differential variation amplitude to eliminate invalid vibration interference, numerical variance is counted and calculated based on direction difference sequence dispersion degree, dynamic stability depth quantitative evaluation of a target area is achieved, and an accurate quantitative index reflecting muscle skin movement coordination is provided. The defect that the micromechanics interaction state is difficult to perceive through macroscopic contour monitoring is overcome.

The invention discloses a novel monitoring and intervention system for parathyroid gland function protection in a thyroid cancer operation, which comprises a nerve monitoring module, a measurement module, a light regulation and control module, an index monitoring module, a data regulation and control module, an intelligent feedback module and a postoperative monitoring module, comprising parathyroid gland specific fluorescent dye and a near-infrared light imaging system and is used for visualizing parathyroid glands in real time during an operation, and the measuring module is used for measuring the concentration value of calcium ions in a measured solution in real time and uploading the concentration value to the system to be stored and collected; blood circulation index data, lactic acid level data and peripheral perfusion parameters are collected through the index monitoring module, the accuracy and diversity of data collection in the operation process are improved, real-time field data collection is conducted on an operation site, and related blood circulation state data are collected through the measurement module and the light regulation and control module.

The invention discloses a thyroid cancer and lymph node accurate positioning system based on three-dimensional imaging, which relates to the technical field of medical image modeling, and comprises the following steps: acquiring two-dimensional images of a cross section and a coronal plane, preprocessing the acquired two-dimensional images, extracting image features of the preprocessed two-dimensional images, and constructing a three-dimensional model based on the image features. Evaluating and adjusting the constructed three-dimensional model, displaying the adjusted three-dimensional model by using a visual tool and providing an interaction tool, generating an electronic diagnosis report based on a three-dimensional model positioning result, storing the generated electronic diagnosis report to a hospital internal database, and performing encryption measures on the access authority of the hospital internal database. According to the thyroid gland and lymph gland positioning method, feature processing is performed based on the preprocessed image, the three-dimensional model is constructed based on the feature processing result, and the adjusted three-dimensional model is displayed by using the visual tool, so that the accuracy of thyroid gland and lymph gland positioning is improved, and the complexity of an operation and the risk of lymph gland omission are reduced.

The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer associated with FBOX21 mediated p85a ubiquitination such as, for example, cancer (e.g., sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The endoscopic thyroid cancer operation trachea retractor comprises a retractor rod, a handle and a retractor head, and an airflow channel is formed in the retractor rod; the handle is formed on the retractor rod and is used for being held by an operator; the retractor head is formed at one end of the retractor rod and used for dragging a trachea; a suction connector is formed in the other end of the draw hook rod and is used for connecting a suction device; a first vent hole is formed in the handle, a second vent hole is formed in the retractor head, and the first vent hole and the second vent hole are both communicated with the airflow channel and are configured to enable the second vent hole to generate negative pressure or release negative pressure by pressing or releasing pressing of the first vent hole. The trachea is hooked by the retractor head to expose an affected part, so that an operator can clearly observe the affected part; by pressing or relieving pressing of the first vent hole, negative pressure can be generated or relieved at the second vent hole conveniently and quickly, so that an operator sucks smoke conveniently and quickly, the operation process is simplified, the operation time is shortened, and the operation efficiency is improved.

This invention discloses a method for constructing a gene methylation diagnostic model for differentiated thyroid cancer (PTC). The method includes the following steps: S1, obtaining a test sample; S2, extracting and storing DNA from the test sample; S3, performing methylation analysis; S4, establishing a diagnostic model based on DNA methylation, where the model shows that patients with cg03596178, cg06033721, cg06688989, cg07209244, cg07485775, cg14484681, cg19979108, and cg20943461 are more likely to experience disease progression and are considered risk factors; S5, cross-validating and evaluating the performance to obtain the gene methylation diagnostic model. This model, by detecting and statistically analyzing specific methylation sites, can differentiate patients with recurrent or metastatic characteristics in differentiated thyroid cancer. The relevant model can assist in the clinical diagnosis and follow-up of thyroid patients.

This disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof, methods for preparing the same, and their use in the treatment and / or diagnosis of cancers such as neuroblastoma, prostate cancer, pancreatic cancer, leukemia, osteosarcoma, hepatoblastoma, lung cancer, colon cancer, breast cancer, skin cancer, thyroid cancer, and / or rhabdoid cancer. JPEG2026522940000099.jpg50170

The invention provides a methylation marker combination for identifying and diagnosing benign and malignant thyroid nodules or diagnosing thyroid cancer. The methylation marker combination comprises methylation TSHR, NIS and TPO genes or fragments thereof. In addition, the invention further provides a thyroid cancer diagnosis product and device based on the methylation marker combination and application of the thyroid cancer diagnosis product and device in thyroid nodule benign and malignant identification and thyroid cancer diagnosis. Whether a thyroid tissue sample or a blood sample is taken as a detection object, the methylation marker combination can realize efficient and sensitive diagnosis of thyroid cancer, and especially has outstanding performance in early thyroid cancer diagnosis, so that the methylation marker combination has a good application prospect. And the kit has important clinical application value and practical significance for early screening and diagnosis of thyroid cancer.

The invention relates to the technical field of fusion gene detection, and discloses a high-throughput detection platform of a thyroid cancer specific fusion gene CCDC6. According to the detection platform disclosed by the invention, high-throughput and high-sensitivity detection on the thyroid cancer CCDC6 fusion gene is realized through a technical scheme of combining sample enrichment and deep learning recognition. Through combination of the sample enrichment module and the deep learning recognition module, the sample enrichment module promotes high-sensitivity recognition of the deep learning recognition module, an end-to-end integrated solution is provided, a large number of samples can be processed in one-time operation, the result can be automatically interpreted, and the detection efficiency and accuracy of the CCDC6 fusion gene are remarkably improved.

The application discloses a thyroid cancer gene detection report intelligent risk assessment method, and relates to the technical field of biomedical information processing, and comprises the following steps: risk conclusion extraction is carried out on obtained multiple thyroid cancer gene detection reports, and the risk conclusion in each detection report is arranged in order of detection time, the time interval between adjacent detection reports is marked, and continuous risk change records are formed. Through time sequence processing and trend reversal identification, the application realizes dynamic analysis of risk assessment, can capture reversal signals in the early stage of risk increase, and improves the timeliness and reliability of risk identification. By setting a reference point and a risk control entrance, combining time interval insertion and detection frequency improvement, the application realizes adaptive correction and continuous updating of risk results, and enhances the real-time performance and safety of risk assessment.

A multi-modal pan-cancer early prediction method is disclosed, comprising: collecting cfDNA samples of i cancer populations and healthy populations respectively and extracting methylation data; merging CpG sites based on the methylation data to obtain multiple methylation intervals, screening multiple candidate marker intervals from the multiple methylation intervals, and further screening the multiple candidate marker intervals; training a first prediction model using the multiple candidate marker intervals, training a second prediction model based on the fragmentation characteristics of the chromosomes extracted from the reference genome, and training a third prediction model by extracting the methylation entropy characteristics of the chromosomes; training a multi-modal pan-cancer early prediction model through the cancer population prediction values of the first prediction model, the second prediction model and the third prediction model, which can provide precise joint early screening for lung cancer, intestinal cancer, gastric cancer, liver cancer, esophageal cancer, thyroid cancer and ovarian cancer.

Disclosed is a method for treating thyroid cancer by using a fibroblast activation protein inhibitor modified with radiolabeled truncated Evans blue. The drug demonstrates good safety and tolerability in thyroid cancer patients, offering excellent therapeutic prospects in the treatment of thyroid cancer.

This invention discloses a traditional Chinese medicine composition, preparation, and its application in the preparation of a drug for treating postoperative cancer-related fatigue in thyroid cancer patients. The traditional Chinese medicine composition comprises the following components in parts by weight: 30-50 parts raw Astragalus membranaceus, 5-20 parts stir-fried Atractylodes macrocephala, 5-20 parts Curculigo orchioides, 5-20 parts Epimedium brevicornu, 5-20 parts Prunella vulgaris, 5-20 parts Dendrobium nobile, and 5-20 parts Lycium barbarum. This invention combines raw Astragalus membranaceus, stir-fried Atractylodes macrocephala, Curculigo orchioides, Epimedium brevicornu, Prunella vulgaris, Dendrobium nobile, and Lycium barbarum. Through the rational combination of these raw materials, it can effectively improve immune function, relieve physical and mental fatigue, and improve the quality of life of postoperative thyroid cancer patients.

The invention relates to an application of LINC01355, miR-27b-3p and POGZ in diagnosis and treatment of thyroid cancer. Specifically, the invention provides an application of LINC01355, miR-27b-3p and POGZ markers or a combination thereof in the occurrence risk of thyroid cancer, and also provides a detection reagent or a kit and risk assessment equipment for assessing the occurrence risk of thyroid cancer. The invention also provides a treatment method of combining the LINC01355 expression promoter, the miR-27b-3p inhibitor and the POGZ expression promoter. The treatment method disclosed by the invention has a remarkable treatment effect on the thyroid cancer.